Safety, efficacy and cost of two direct-acting antiviral regimens: A comparative study in chronic hepatitis C Egyptian patients.
Abdel-Hameed Ibrahim Mohammed EbidOsama Ashraf AhmedSara Hassan AgwaSara Mohamed Abdel-MotalebAmira Mohamed ElsawyRadwa Samir HagagPublished in: Journal of clinical pharmacy and therapeutics (2019)
The two DAA regimens showed high SVR12 and safety in Egyptian HCV G4 patients. Sofosbuvir plus daclatasvir is the cost-saving regimen.